Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Rivaroxaban in acute coronary syndromes--is it prime time?

Asrar ul Haq M, van Gaal WJ.

Expert Rev Cardiovasc Ther. 2014 Jun;12(6):649-58. doi: 10.1586/14779072.2014.910118. Epub 2014 Apr 19. Review.

PMID:
24746010
2.

The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.

Reddy P, Giugliano RP.

J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):526-32. doi: 10.1177/1074248414525505. Epub 2014 Mar 21. Review.

PMID:
24659084
3.

Potential role of rivaroxaban in patients with acute coronary syndrome.

Fitchett DH.

Drug Des Devel Ther. 2012;6:349-57. doi: 10.2147/DDDT.S30342. Epub 2012 Nov 22. Review.

4.

Novel oral anticoagulants in acute coronary syndrome.

Costopoulos C, Niespialowska-Steuden M, Kukreja N, Gorog DA.

Int J Cardiol. 2013 Sep 10;167(6):2449-55. doi: 10.1016/j.ijcard.2012.08.014. Epub 2012 Sep 16. Review.

PMID:
22989603
6.

Rivaroxaban for the treatment of acute coronary syndromes.

Wong CK, White HD.

Expert Opin Pharmacother. 2013 May;14(7):917-27. doi: 10.1517/14656566.2013.780029. Epub 2013 Apr 2. Review.

PMID:
23544968
7.

Rivaroxaban: a review of its use in acute coronary syndromes.

Plosker GL.

Drugs. 2014 Mar;74(4):451-64. doi: 10.1007/s40265-014-0188-6. Review.

PMID:
24535922
8.

Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).

Mega JL, Braunwald E, Murphy SA, Plotnikov AN, Burton P, Kiss RG, Parkhomenko A, Tendera M, Widimsky P, Gibson CM.

J Am Coll Cardiol. 2013 May 7;61(18):1853-9. doi: 10.1016/j.jacc.2013.01.066. Epub 2013 Mar 7.

9.

Rivaroxaban in patients with a recent acute coronary syndrome.

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators.

N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13.

10.

The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.

Cohen M, Iyer D.

Cardiovasc Ther. 2014 Oct;32(5):224-32. doi: 10.1111/1755-5922.12083. Review.

11.

Rivaroxaban (Xarelto) for acute coronary syndrome.

[No authors listed]

Med Lett Drugs Ther. 2011 Dec 12;53(1379-1380):97.

PMID:
22173426
12.
13.

Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.

Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP, Verheugt FW, Bhatt DL, Goto S, Cohen M, Mohanavelu S, Burton P, Stone G, Braunwald E; ATLAS-ACS 2 TIMI 51 Investigators.

J Am Coll Cardiol. 2013 Jul 23;62(4):286-90. doi: 10.1016/j.jacc.2013.03.041. Epub 2013 Apr 16.

14.

Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51).

Mega JL, Braunwald E, Wiviott SD, Murphy SA, Plotnikov A, Gotcheva N, Ruda M, Gibson CM.

Am J Cardiol. 2013 Aug 15;112(4):472-8. doi: 10.1016/j.amjcard.2013.04.011. Epub 2013 May 24.

PMID:
23711804
15.

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM; ATLAS ACS-TIMI 46 study group.

Lancet. 2009 Jul 4;374(9683):29-38. doi: 10.1016/S0140-6736(09)60738-8. Epub 2009 Jun 17.

PMID:
19539361
16.

Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice.

Shivu GN, Ossei-Gerning N.

Vasc Health Risk Manag. 2014 May 12;10:291-302. doi: 10.2147/VHRM.S59420. eCollection 2014. Review.

17.

Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.

Turpie AG.

Expert Rev Cardiovasc Ther. 2014 Aug;12(8):963-76. doi: 10.1586/14779072.2014.938055. Epub 2014 Jul 12. Review.

PMID:
25017622
18.

Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.

Martínez-Rubio A, Dan GA, Kaski JC.

Expert Rev Cardiovasc Ther. 2014 Aug;12(8):933-47. doi: 10.1586/14779072.2014.931223. Epub 2014 Jun 19. Review.

PMID:
24948333
20.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk